Table 4.

Risk of All-cause Mortality Associated with Different Patterns of Myocardial Infarction.

	Events/1000 person years	Model 1* HR (95% CI)	Model 2 † HR (95% CI)	Interaction P-value††
All participants				N/A
No MI (n=8,795)	8.4	1 (ref.)	1 (ref.)
Silent MI (n=317)	15.9	1.63 (1.33–1.99)	1.34 (1.09–1.65)
Clinical MI (n=386)	18.7	1.85 (1.56–2.20)	1.55 (1.30–1.85)
Men				0.051
No MI (n=3,641)	11.0	1 (ref.)	1 (ref.)
Silent MI (n=178)	17.3	1.43 (1.11–1.85)	1.23 (0.94–1.60)
Clinical MI (n=279)	18.7	1.65 (1.34–2.02)	1.45 (1.18–1.78)
Women
No MI (n=5,154)	6.6	1 (ref.)	1 (ref.)
Silent MI (n=139)	14.0	2.05 (1.49–2.81)	1.58 (1.13–2.20)
Clinical MI (n=107)	18.9	2.59 (1.89–3.56)	1.83 (1.32–2.54)
White				0.178
No MI (n=6,993)	8.0	1 (ref.)	1 (ref.)
Silent MI (n=243)	14.6	1.50 (1.18–1.90)	1.31 (1.03–1.67)
Clinical MI (n=332)	18.1	1.80 (1.49–2.17)	1.48 (1.22–1.79)
Black
No MI (n=1,802)	9.8	1 (ref.)	1 (Ref.)
Silent MI (n=74)	20.1	2.03 (1.40–2.96)	1.45 (0.96–2.21)
Clinical MI (n=54)	23.0	2.14 (1.41–3.26)	1.97 (1.27–3.05)

HR=hazard ratio; CI=confidence interval; MI= myocardial infarction

^*Model 1 adjusted for age, sex, and race.

^†Model 2 adjusted for variables in model 1 plus study field center, body mass index, education, smoking status, systolic blood pressure, blood pressure lowering medications, diabetes mellitus, ratio of total cholesterol/high density lipoprotein, use of cholesterol lowering medications, use of aspirin, family history of coronary heart disease and serum creatinine (all at baseline).

^††Interactions tested in Model 2.